FROM 01 Nov, Jardiance (empagliflozin 10mg) will be listed on the Pharmaceutical Benefits Scheme (PBS) for the treatment of chronic kidney disease (CKD) in adults at moderate-to-severe risk of their condition worsening.
It is expected that 70,000 Australians with CKD will be eligible to access the medicine, with Professor Eugenia Pedagogos, a Melbourne Nephrologist and Medical Director at Epworth Freemasons Hospital, among those welcoming the expanded medicine subsidy.
"Thousands of Australians with varying stages of chronic kidney disease can now access an affordable treatment through the PBS for the first time," Prof Pedagogos said.
"This marks an important milestone for Australians with chronic kidney disease, ensuring access to care from the earlier stages of disease to the critical point before dialysis.
"The more we can do to prevent the slippery slope of kidney disease, the better."
The SGLT-2 inhibitor was listed on the PBS in 2024 for a smaller group of Australians with proteinuric CKD.
Earlier this year the drug was listed to allow use from the start in patients with T2D taking metformin who have or are at high risk of cardiovascular disease or are First Nations peoples (PD 02 Apr).
The above article was sent to subscribers in Pharmacy Daily's issue from 28 Oct 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Oct 25
